Finance

Beta
Lists
AMRX:NASDAQ
Amneal Pharmaceuticals Inc
$13.75
+1.70%
(+0.23) 1D
$13.80
+0.36% (+0.050)
After hours
Closed: Jun 5, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AMRX...
Open
$13.58
High
$13.88
Low
$13.55
Mkt. cap
4.39B
Avg. vol.
1.60M
Volume
1.30M
P/E ratio
36.86
52-wk high
$15.42
52-wk low
$7.26
EPS
$0.37
Beta
1.30
Shares outstanding
319.02M
No. of employees
9K
Open
$13.58
High
$13.88
Low
$13.55
Mkt. cap
4.39B
Avg. vol.
1.60M
Volume
1.30M
P/E ratio
36.86
52-wk high
$15.42
52-wk low
$7.26
EPS
$0.37
Beta
1.30
Shares outstanding
319.02M
No. of employees
9K
Analyst outlook
Analyst Ratings
Based on 5 analysts giving stock ratings to AMRX in the past 3 months
Strong Buy
Buy
5
Hold
0
Sell
0
12 month forecast
Based on 5 Wall Street analysts offering 12 month price targets for AMRX in the last 3 months.
Highest
Current $13.75
$19.00 (+38.18%)
Average
$17.25 (+25.45%)
Lowest
$16.00 (+16.36%)
News stories
From sources across the web
Profile
Amneal Pharmaceuticals, Inc. is an American publicly traded pharmaceutical company that develops, manufactures and distributes generics and specialty pharmaceutical products. The company is headquartered in Bridgewater, New Jersey, and is one of the largest manufacturers of generic drugs in the United States. Wikipedia
About Amneal Pharmaceuticals Inc
CEOChintu Patel | Chirag Patel
Employees8.7K
Founded2002
HeadquartersBridgewater, New Jersey, United States
SectorPharmaceutical industry
Websiteamneal.com
Last report
Apr 22, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
$0.27 / $0.17
+59.62%beat
Revenue / Est. (USD)
722.52M / 716.78M
+0.80%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
724.51M
784.51M
814.32M
722.52M
Cost of goods sold
440.27M
490.19M
518.54M
403.95M
Cost of revenue
440.27M
490.19M
518.54M
403.95M
Research and development expenses
47.96M
63.35M
34.79M
38.38M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
124.27M
137.82M
146.48M
138.86M
Operating expense
172.23M
201.05M
181.28M
177.18M
Total operating expenses
612.50M
691.24M
699.82M
581.13M
Operating income
112.01M
93.27M
114.50M
141.39M
Other non operating income
-2.82M
22.04M
876.00K
3.08M
EBT including unusual items
51.71M
-5.22M
55.24M
80.18M
EBT excluding unusual items
52.34M
49.07M
57.70M
83.31M
Income tax expense
16.10M
-23.36M
5.66M
2.18M
Effective tax rate
31.14%
447.16%
10.25%
2.71%
Other operating expenses
-
-117.00K
-1.00K
-64.00K
Net income
22.42M
2.37M
35.08M
62.26M
Net profit margin
3.09%
0.30%
4.31%
8.62%
Earnings per share
0.25
0.17
0.21
0.27
Interest and investment income
-
-
-
-
Interest expense
-65.10M
-62.81M
-56.24M
-53.36M
Net interest expenses
-65.10M
-62.81M
-56.24M
-53.36M
Depreciation and amortization charges
-
-
-
-
EBITDA
172.12M
147.34M
163.73M
184.58M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer